Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.
Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 1 NAI (no action), 0 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (1).
Last updated 2026-03-21. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Who are the top Exosome / Extracellular Vesicle CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Exosome / Extracellular Vesicle CDMOs include Codiak BioSciences (Sarepta). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Exosome / Extracellular Vesicle CDMOs have FDA inspection records?
CDMO Signal tracks 1 Exosome / Extracellular Vesicle CDMO with FDA inspection records and 0 EMA/MHRA GMP certificates across the group.
What should I look for in an exosome CDMO?
Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.
Is exosome manufacturing standardized?
Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.